Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Enzon Pharmaceuticals Inc

+ Add to Watchlist

ENZN:US

3.1700 USD 0.0100 0.31%

As of 20:10:00 ET on 05/17/2013.

Company Profile for Enzon Pharmaceuticals Inc (ENZN)

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company has developed several products, including PEG-INTRON. Enzon's product-focused strategy includes a drug development program that leverages its PEG modification and single-chain antibody (SCA) technologies.

Contact Information

Enzon Pharmaceuticals Inc

20 Kingsbridge Road
Piscataway, NJ 08854
United States
Phone: 1-732-980-4500

Key Executives for Enzon Pharmaceuticals Inc (ENZN)

Ralph Del CampoChief Operating OfficerAndrew RackearChief Compliance Ofcr/Secy
Charles ConoverSenior VP:Research & DevelopmentTimothy G DalyVP/Chief Acctg Ofcr/Controller

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil